"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 3 | 0 | 3 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 4 | 0 | 4 |
| 2006 | 7 | 1 | 8 |
| 2007 | 7 | 1 | 8 |
| 2008 | 5 | 2 | 7 |
| 2009 | 9 | 3 | 12 |
| 2010 | 7 | 6 | 13 |
| 2011 | 15 | 5 | 20 |
| 2012 | 11 | 9 | 20 |
| 2013 | 10 | 5 | 15 |
| 2014 | 5 | 1 | 6 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 4 | 6 |
| 2017 | 3 | 2 | 5 |
| 2018 | 4 | 3 | 7 |
| 2019 | 4 | 0 | 4 |
| 2020 | 3 | 2 | 5 |
| 2021 | 4 | 0 | 4 |
| 2023 | 1 | 1 | 2 |
| 2024 | 7 | 9 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
-
Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease. J Pediatr Gastroenterol Nutr. 2024 Dec; 79(6):1192-1198.
-
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes. 2024 Jan-Dec; 16(1):2399260.
-
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD. Cell Rep Med. 2024 Sep 17; 5(9):101714.
-
Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver disease and diabetes. mSystems. 2024 Sep 17; 9(9):e0043424.
-
Perioperative outcomes after hepatectomy for hepatocellular carcinoma among patients with cirrhosis, fatty liver disease, and clinically normal livers. Surg Oncol. 2024 Oct; 56:102114.
-
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024 Jul 25; 391(4):371-372.
-
An evaluation model of hepatic steatosis based on CT value and serum uric acid/HDL cholesterol ratio can predict intrahepatic recurrence of colorectal cancer liver metastasis. Int J Clin Oncol. 2024 Sep; 29(9):1263-1273.
-
Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis. Eur J Gastroenterol Hepatol. 2024 Aug 01; 36(8):1038-1045.
-
Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality. J Gastroenterol Hepatol. 2024 Sep; 39(9):1950-1956.